Literature DB >> 11891466

Clinical measurement of blood flow in tumours using positron emission tomography: a review.

H Anderson1, P Price.   

Abstract

In oncology drug development there is an increasing need for the in vivo physiological measurement of changes in tumour blood flow in response to therapy. Positron Emission Tomography (PET) is being increasingly used in oncology patients to measure blood flow. Here we review the clinical use of PET to measure vascular parameters in man.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11891466     DOI： 10.1097/00006231-200202000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


  10 in total

1.  Brain perfusion CT compared with ¹⁵O-H₂O PET in patients with primary brain tumours.

Authors:  Julie Marie Grüner; Rune Paamand; Michael Kosteljanetz; Helle Broholm; Liselotte Højgaard; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-27       Impact factor: 9.236

2.  Multimodal optical imaging can reveal changes in microcirculation and tissue oxygenation during skin wound healing.

Authors:  Hequn Wang; Lei Shi; Jia Qin; Siavash Yousefi; Yuandong Li; Ruikang K Wang
Journal:  Lasers Surg Med       Date:  2014-05-01       Impact factor: 4.025

Review 3.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

4.  PET Imaging of Angiogenesis.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  PET Clin       Date:  2009-01-01

5.  Automated synthesis of [68Ga]oxine, improved preparation of 68Ga-labeled erythrocytes for blood-pool imaging, and preclinical evaluation in rodents.

Authors:  Stephen Thompson; Melissa E Rodnick; Jenelle Stauff; Janna Arteaga; Timothy J Desmond; Peter J H Scott; Benjamin L Viglianti
Journal:  Medchemcomm       Date:  2018-02-01       Impact factor: 3.597

6.  Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.

Authors:  Azeem Saleem; Julian C Matthews; Malcolm Ranson; Sophie Callies; Valérie André; Michael Lahn; Claire Dickinson; Christian Prenant; Gavin Brown; Adam McMahon; Denis C Talbot; Terry Jones; Patricia M Price
Journal:  Theranostics       Date:  2011-06-01       Impact factor: 11.556

Review 7.  Methodology for quantitative rapid multi-tracer PET tumor characterizations.

Authors:  Dan J Kadrmas; John M Hoffman
Journal:  Theranostics       Date:  2013-10-04       Impact factor: 11.556

8.  Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy.

Authors:  Nanda Krak; Jacobus van der Hoeven; Otto Hoekstra; Jos Twisk; Elsken van der Wall; Adriaan Lammertsma
Journal:  Mol Imaging Biol       Date:  2008-08-16       Impact factor: 3.488

9.  Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.

Authors:  Ashley M Groves; Gordon C Wishart; Manu Shastry; Penelope Moyle; Sharon Iddles; Peter Britton; Mathew Gaskarth; Ruth M Warren; Peter J Ell; Kenneth A Miles
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-26       Impact factor: 9.236

10.  Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

Authors:  H Anderson; J T Yap; P Wells; M P Miller; D Propper; P Price; A L Harris
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.